Please login to the form below

Not currently logged in
Email:
Password:

Arterial

This page shows the latest Arterial news and features for those working in and with pharma, biotech and healthcare.

BTG acquires Roxwood Medical

BTG acquires Roxwood Medical

With the expanded commercial and clinical reach of BTG, these minimally invasive tools can help far more clinicians successfully treat patients with severe arterial blockages.”.

Latest news

More from news
Approximately 5 fully matching, plus 88 partially matching documents found.

Latest Intelligence

  • Is it time we stopped talking about adherence? Is it time we stopped talking about adherence?

    The EarthWorks has employed this philosophy to develop award-winning patient support programmes in chronic conditions such as asthma and HIV, and rare, complex conditions such as pulmonary arterial hypertension.

  • Mobile health and patient outcomes Mobile health and patient outcomes

    diabetes patients to remember their nutritional plan when in a supermarket or advising patients with pulmonary arterial hypertension that their average six-minute walking distance has decreased, prompting them to speak

  • The three forces behind the re-imagining of patient care The three forces behind the re-imagining of patient care

    Using apps to manage chronic conditions such as diabetes and asthma and rare disease such as pulmonary arterial hypertension can now be proven to improve clinical care.

  • Pharma deals in September 2015 Pharma deals in September 2015

    In an attempt to be hunter rather than hunted, and to diversify its portfolio from just PAH (pulmonary arterial hypertension), Actelion has acknowledged it is holding “ preliminary discussions with ZS Pharma”.

  • Deal Watch table for June 2013 Deal Watch table for June 2013

    75. Taiwan Liposome Company / SciClone Pharmaceuticals. Exclusive licence. Commercialisation of ProFlow (lipid emulsion-based formulation of alprostadil) for peripheral arterial disease (approved Taiwan).

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest appointments

  • Former Novartis vaccines CMO joins Arterial Former Novartis vaccines CMO joins Arterial

    Former Novartis vaccines CMO joins Arterial. Dr Markus Weissbach becomes clinical trials director. ... Arterial Capital Management, a life science-focused private equity firm, has appointed Dr Markus Weissbach as clinical trials director and a member of

  • Kite Pharma appoints Zelboraf scientist as CMO Kite Pharma appoints Zelboraf scientist as CMO

    Prior to joining Plexxikon, Dr Nolop was VP of clinical research at CoTherix, where he led the development and US approval for Ventavis (iloprost) to treat pulmonary arterial hypertension (PAH).

More from appointments
Approximately 1 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Lucid Group Communications Limited

We are industry-leading thinkers when it comes to education. We use the latest academic thinking on the psychology of behaviour...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics